益安喜

Yianxi Biotech is a clinical-stage biotechnology company based in Suzhou, China, focused on developing breakthrough cell therapies for solid tumors. The company utilizes advanced genetic engineering to create "armored" CAR-T cells designed to overcome the immunosuppressive barriers of the tumor microenvironment. Its lead program, YAX-101, targets Glypican-3 (GPC3) and is currently being evaluated in clinical trials for patients with advanced liver cancer. By integrating innovative design with robust manufacturing processes, Yianxi Biotech seeks to expand the efficacy of immune cell therapies beyond blood cancers into a wide range of solid malignancies. The company's pipeline also includes candidates targeting Claudin 18.2 for gastric and pancreatic cancers.